Alligator Bioscience
Biotechnology Research • 
Lund, Skåne County, Sweden • 21-50 Employees
Company overview
| Headquarters | Lund, Skåne County, Sweden |
| Phone number | +46465408200 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Immuno-Oncology, Combination Therapy, Immunotherapy Of Cancer, Cd40 |
| Founded | 2001 |
| Employees | 21-50 |
| Socials |
Key Contacts at Alligator Bioscience
Denise Goode
Non Executive Director
Yago Pico De Coaña
Medical Science Director
Karin Nordbladh
Employee Representative Board Of Directors, Alligator Bioscience
Per-Anders Johansson
Sr Director Cmc
Alligator Bioscience Email Formats
Alligator Bioscience uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@alligatorbioscience.com), used 80% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@alligatorbioscience.com | 80% |
{first initial}.{last name} | j.doe@alligatorbioscience.com | 20% |
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.
Alligator Bioscience revenue & valuation
| Annual revenue | $5,244,342 |
| Revenue per employee | $188,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $16,800,000 |
| Total funding | $10,400,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Alligator Bioscience has 10 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore Alligator Bioscience's funding history, including investment rounds, total capital raised, and key backers.
Alligator Bioscience Tech Stack
Discover the technologies and tools that power Alligator Bioscience's digital infrastructure, from frameworks to analytics platforms.
CDN
Performance
Security
JavaScript libraries
Miscellaneous
Programming languages
Miscellaneous
Translation
Blogs
UI frameworks
Maps
Databases
United States
Norway
Frequently asked questions
4.8
40,000 users
